This article is more than 5 years old. Information may no longer be current.

FDA approves EyeGate PRK pivotal study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved a PRK pivotal clinical study from EyeGate Pharmaceuticals, according to a press release.

The company’s OBG platform, based on cross-linked thiolated carboxymethyl hyaluronic acid, helps with hydrating and healing the ocular surface. It is suited for ocular surface injuries because it adheres longer to the ocular surface, resists degradation and protects the ocular surface, the release said.

“We expect to receive topline results by year-end 2019 and, assuming these are positive, plan to submit a de novo application for commercialization shortly thereafter,” EyeGate CEO Stephen From said in the release. “Our OBG platform, if approved, will be the first prescription hyaluronic acid eye drop formulation in the U.S. market, providing a huge opportunity for us.”

The company will modify the patient informed consent document to comply with requests from the FDA before beginning study enrollment this month, the release said.